

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Atty Docket No. 104385.140)

In Re:

Application of: Bennett et al.

Serial Number: 08/722,659

Filed: September 27, 1996

For: USE OF HEPARINASE TO DECREASE INFLAMMATORY RESPONSES



Group Art Unit: 1644

Examiner: Ewoldt, G.

Assistant Commissioner for Patents
Washington, D.C. 20231

35

TERMINAL DISCLAIMER

I, Robert A. Heft, Ph.D., declare that I am the President and Chief Operating Officer of IBEX Technologies, Inc., the assignee of all rights and interest in the above-referenced patent application, as recorded on Reel 8857, Frame 0657, that the evidentiary documents have been reviewed and that I certify, to the best of my knowledge and belief, title is in IBEX Technologies, Inc., and that I am authorized to execute this Terminal Disclaimer on behalf of IBEX Technologies, Inc.

Pursuant to 35 U.S.C. §253 and 37 C.F.R. §1.321, IBEX Technologies, Inc. hereby disclaims the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of any patent granted on United States Letters Patent No. 5,997,863. Further, pursuant to 37 C.F.R. § 1.321(c)(3), this terminal disclaimer is filed to obviate a double patenting rejection in the above-referenced patent application. Any patent granted on the above-referenced application or any resulting patent subject to reexamination proceedings shall be enforceable only for and during such period that said patent is commonly owned with the application or patent which formed the basis for the rejection.

Petitioner does not disclaim any terminal part of any patent granted on the subject application prior to the expiration date of the full statutory term of any patent granted on United States Letters Patent No. 5,997,863, in the event that either later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.32(a), has all claims cancelled by a reexamination

certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Respectfully submitted,



Robert A. Heft, Ph.D.
President and Chief Operating Officer
IBEX Technologies, Inc.

Dated: July 31, 2001